Portal de Periódicos da CAPES

In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

2020; Elsevier BV; Volume: 145; Linguagem: Inglês

10.1016/j.micpath.2020.104228

1096-1208

Julien Andréani, Marion Le Bideau, Isabelle Duflot, Priscilla Jardot, Clara Rolland, Manon Boxberger, Nathalie Wurtz, Jean‐Marc Rolain, Philippe Colson, Bernard La Scola, Didier Raoult,

Infectious Encephalopathies and Encephalitis

Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.